Vabomere (meropenem and vaborbactam; The Medicines Company) is now available for the treatment of adults (≥18 years old) with complicated urinary tract infections, including pyelonephritis, caused by susceptible Enterobacteriaceae: Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex.
This combination antibiotic includes meropenem, a penem antibacterial, and vaborbactam, a non-suicidal beta-lactamase inhibitor. Meropenem inhibits cell wall synthesis and vaborbactam protects meropenem from degradation by specific serine beta-lactamases; it has no antibacterial activity.
Vabomere for injection is supplied as a sterile powder for constitution in single-dose vials containing meropenem 1g (equivalent to 1.14g of meropenem trihydrate) and vaborbactam 1g. Vabomere does not contain preservatives. Aseptic technique must be used for constitution and dilution.
For more information visit Vabomere.com.